ライフサイエンスコーパス: cardiac arrhythmia

1 den death syndromes like SUDEP and SIDS, and cardiac arrhythmia.

2 including hypertension, angina pectoris, and cardiac arrhythmia.

3 to reduced muscle performance and to marked cardiac arrhythmia.

4 uences on autonomic outflow, contributing to cardiac arrhythmia.

5 and is associated with an increased risk of cardiac arrhythmia.

6 pilepsy, bipolar disorder, chronic pain, and cardiac arrhythmia.

7 brillation (AF) is the most common sustained cardiac arrhythmia.

8 imately lead to novel therapeutics targeting cardiac arrhythmia.

9 Atrial fibrillation is the most common cardiac arrhythmia.

10 orm for investigating the basis of reentrant cardiac arrhythmia.

11 the initiation and maintenance of reentrant cardiac arrhythmia.

12 ong-QT syndrome (LQTS), a potentially lethal cardiac arrhythmia.

13 heart rate variability could protect against cardiac arrhythmia.

14 in the elderly group died after surgery from cardiac arrhythmia.

15 ated associations between air pollutants and cardiac arrhythmia.

16 Atrial fibrillation (AF) is the most common cardiac arrhythmia.

17 rents in sinoatrial nodal (SAN) cells causes cardiac arrhythmia.

18 ed more light onto this mechanism leading to cardiac arrhythmia.

19 an mutations in SCN1B result in epilepsy and cardiac arrhythmia.

20 table mutations cause periodic paralysis and cardiac arrhythmia.

21 g neurodevelopmental disorders, dwarfism and cardiac arrhythmia.

22 d to long QT syndrome (LQTS), a catastrophic cardiac arrhythmia.

23 ial fibrillation is the most common clinical cardiac arrhythmia.

24 l fibrillation is the most prevalent form of cardiac arrhythmia.

25 lectrical conduction that may be involved in cardiac arrhythmia.

26 atrial fibrillation (AF), the most frequent cardiac arrhythmia.

27 tified in patients with Long QT syndrome and cardiac arrhythmia.

28 cardiomyocytes, resulting in a substrate for cardiac arrhythmia.

29 , heart failure, vascular complications, and cardiac arrhythmia.

30 -mediated severe hypoglycemia induces lethal cardiac arrhythmias.

31 as key players in beta-adrenergic-dependent cardiac arrhythmias.

32 ten a precursor to the initiation of serious cardiac arrhythmias.

33 ADs) are voltage oscillations known to cause cardiac arrhythmias.

34 alogs could be developed into drugs to treat cardiac arrhythmias.

35 stress, it can also trigger life-threatening cardiac arrhythmias.

36 athogenesis of heart failure and a number of cardiac arrhythmias.

37 ovel possible mechanism for intermittency of cardiac arrhythmias.

38 hannels within the heart to epilepsy-related cardiac arrhythmias.

39 lonus-dystonia-like syndrome associated with cardiac arrhythmias.

40 fected by a unique dominant M-D syndrome and cardiac arrhythmias.

41 arization, blocking these channels may cause cardiac arrhythmias.

42 and targets for diseases such as cancer and cardiac arrhythmias.

43 ng illness that may lead to heart failure or cardiac arrhythmias.

44 sociated with epilepsy syndromes, autism and cardiac arrhythmias.

45 ) is one of the most severe life-threatening cardiac arrhythmias.

46 ndrome is a long QT interval that results in cardiac arrhythmias.

47 (Cav1) gene variants with increased risk of cardiac arrhythmias.

48 ly afterdepolarizations (EADs) are linked to cardiac arrhythmias.

49 tations resulting in susceptibility to fatal cardiac arrhythmias.

50 nt further investigation in the treatment of cardiac arrhythmias.

51 eate a substrate favoring the development of cardiac arrhythmias.

52 esulting in impaired contractility and fatal cardiac arrhythmias.

53 al restriction of dietary magnesium increase cardiac arrhythmias.

54 y factors contributing to the development of cardiac arrhythmias.

55 to dysregulation of calcium homeostasis and cardiac arrhythmias.

56 erived cardiomyocytes (iPSC-CM) as models of cardiac arrhythmias.

57 art may play an important role in sustaining cardiac arrhythmias.

58 ease is the primary cause of RyR2-associated cardiac arrhythmias.

59 x43) genes (GJA5 and GJA1, respectively) and cardiac arrhythmias.

60 inherited mutation can underlie and trigger cardiac arrhythmias.

61 se channel subunits lead to life-threatening cardiac arrhythmias.

62 on thereby predisposing to heart disease and cardiac arrhythmias.

63 rged as the basis for a variety of inherited cardiac arrhythmias.

64 localization are linked to potentially fatal cardiac arrhythmias.

65 QT syndrome, respectively, leading to fatal cardiac arrhythmias.

66 evere skeletal muscle disorders or triggered cardiac arrhythmias.

67 ardiac conduction and the predisposition for cardiac arrhythmias.

68 ges might represent a new strategy to combat cardiac arrhythmias.

69 vels, have been linked to the development of cardiac arrhythmias.

70 al developmental delays, cryptorchidism, and cardiac arrhythmias.

71 hysiology of the heart and in the genesis of cardiac arrhythmias.

72 ongestive heart failure or die suddenly from cardiac arrhythmias.

73 in the membrane as an approach for treating cardiac arrhythmias.

74 on in the ventricle and predispose to lethal cardiac arrhythmias.

75 sly identified KCNE2- and KCNQ1-linked human cardiac arrhythmias.

76 mal diagnosis and treatment to patients with cardiac arrhythmias.

77 luding epilepsy, chronic pain, myotonia, and cardiac arrhythmias.

78 ll-cell coupling and reduce ischemia-related cardiac arrhythmias.

79 o-related gene 1, hERG1, are associated with cardiac arrhythmias.

80 the placebo group in rates of hypotension or cardiac arrhythmias.

81 er the molecular mechanisms and treatment of cardiac arrhythmias.

82 ia reduced fatal severe hypoglycemia-induced cardiac arrhythmias.

83 lcium (Ca(2+)) ions mediate various types of cardiac arrhythmias.

84 festations of triggered activity relevant to cardiac arrhythmias.

85 cardiac repolarization and life-threatening cardiac arrhythmias.

86 modeling observed in patients suffering from cardiac arrhythmias.

87 profiles associated with various (post)ictal cardiac arrhythmias.

88 ion potential and potentially trigger lethal cardiac arrhythmias.

89 itable tissues, such as the heart, producing cardiac arrhythmias.

90 yed afterdepolarizations (DADs) that trigger cardiac arrhythmias.

91 ion potential and potentially trigger lethal cardiac arrhythmias.

92 re instrumental in determining mechanisms of cardiac arrhythmias.

93 metallic nanoparticles for the treatment of cardiac arrhythmias.

94 ired long QT syndrome that can lead to fatal cardiac arrhythmias.

95 cation channels and are linked to inherited cardiac arrhythmias.

96 ropensity for spontaneous Ca(2+) release and cardiac arrhythmias.

97 5% confidence interval (CI): 0.54, 3.44) and cardiac arrhythmia (1.65%, 95% CI: 0.37, 2.95) increased

98 sed by neurally mediated syncope (37.3%) and cardiac arrhythmias (11.8%).

99 ency heart rate variability (LF/HFHRV )] and cardiac arrhythmias (196.0 +/- 239.9 vs. 19.8 +/- 21.7 e

100 vs. hypercapnia, respectively), incidence of cardiac arrhythmias (196.0 +/- 239.9 vs. 576.7 +/- 472.9

101 3.0% vs 42.7%; OR, 1.01; 95% CI, 0.98-1.05), cardiac arrhythmias (25.8% vs 26.0%; OR, 0.99; 95% CI, 0

102 9%; P=0.006) and an increase in frequency of cardiac arrhythmia (40.4% versus 31.4%; P=0.05).

103 events (14 vs 4, respectively; P = .02) and cardiac arrhythmias (57 vs 30; P = .004).

104 shown it to be useful in patients undergoing cardiac arrhythmia ablations, interventional radiology p

105 ation of betaARs increases the likelihood of cardiac arrhythmias, adverse ventricular remodelling, de

106 V-infected persons; however, the most common cardiac arrhythmia, AF, has not been adequately studied

107 Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting >2 million patients in the

108 Oxidative stress has been implicated in cardiac arrhythmia, although a causal relationship remai

109 Atrial fibrillation (AF) is a common cardiac arrhythmia and a major risk factor for stroke, h

110 Atrial fibrillation is the most common cardiac arrhythmia and conveys a significant risk of mor

111 cases have clinically relevant mutations in cardiac arrhythmia and epilepsy genes.

112 several cardiovascular disorders, including cardiac arrhythmia and heart failure.

113 in uterine artery blood flow associated with cardiac arrhythmia and high magnitude irregular fluctuat

114 Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a 5-fold incre

115 Atrial fibrillation is the most common cardiac arrhythmia and leads to stroke.

116 gene causing a very rare autosomal recessive cardiac arrhythmia and LGMD, expanding the genetic cause

117 hole-exome sequencing, in a family of 4 with cardiac arrhythmia and limb-girdle muscular dystrophy (L

118 rited long QT syndrome and increased risk of cardiac arrhythmia and sudden death.

119 me that predisposes afflicted individuals to cardiac arrhythmia and sudden death.

120 cated in human disease, including hereditary cardiac arrhythmia and type 2 diabetes (T2D).

121 mal cardiac electrophysiology and to prevent cardiac arrhythmias and AF.

122 witnessed an explosion in interest regarding cardiac arrhythmias and air pollution.

123 azepines are used primarily for treatment of cardiac arrhythmias and are thought to physically block

124 nically reported as a risk factor for lethal cardiac arrhythmias and arrhythmic death.

125 treated, life-threatening complications like cardiac arrhythmias and broncholaryngospasm may occur.

126 ations in FHFs may underlie a similar set of cardiac arrhythmias and cardiomyopathies that result fro

127 a large number of mutations associated with cardiac arrhythmias and cardiomyopathies.

128 us comorbidities, eg, chronic heart failure, cardiac arrhythmias and chronic renal failure.

129 Death was associated with spontaneous cardiac arrhythmias and complete conduction block.

130 beta-Adrenergic blockade markedly reduced cardiac arrhythmias and completely abrogated deaths due

131 Cardiac arrhythmias and conduction disturbances are acco

132 erlies diverse ion channelopathies including cardiac arrhythmias and cystic fibrosis.

133 ut this study identified 2 novel predictors: cardiac arrhythmias and depression.

134 th arrhythmogenic cardiomyopathy who exhibit cardiac arrhythmias and dysfunction, palmoplanter kerato

135 a diverse set of channelopathies, including cardiac arrhythmias and epilepsy syndromes.

136 ongenital channelopathies, such as deafness, cardiac arrhythmias and epilepsy.

137 lay an important role in the pathogenesis of cardiac arrhythmias and may also contribute to the devel

138 would ensure prevention of sudden death from cardiac arrhythmias and other complications.

139 channels and abnormal sodium homeostasis in cardiac arrhythmias and pharmacotherapy from the subcell

140 CMP and non-PPCMP patients except for higher cardiac arrhythmias and respiratory failure in the non-P

141 E inhibition and at higher concentrations to cardiac arrhythmias and seizures due to adenosine A1-rec

142 CaT) amplitude, is a high risk indicator for cardiac arrhythmias and sudden cardiac death.

143 CaT) amplitude--is a high risk indicator for cardiac arrhythmias and sudden cardiac death.

144 tance and coupling, and is a risk factor for cardiac arrhythmias and sudden cardiac death.

145 KCNQ1 results in increased susceptibility to cardiac arrhythmias and sudden death with or without acc

146 s on the ECG and increased susceptibility to cardiac arrhythmias and sudden death.

147 olarization that can lead to long QT2 (LQT2) cardiac arrhythmias and sudden death.

148 nt of the myocardium and a predisposition to cardiac arrhythmias and sudden death.

149 g QT syndrome (LQTS) and are associated with cardiac arrhythmias and sudden death.

150 drome (TS), a rare disorder characterized by cardiac arrhythmias and syndactyly, highlighted unexpect

151 e impact it has already had on the fields of cardiac arrhythmias and whole-heart computational modeli

152 July 2013 on the combination of two terms: 'cardiac arrhythmias' and 'epilepsy'.

153 rt failure, peripheral vascular disease, and cardiac arrhythmia) and neuropsychiatric (depression and

154 de because of transient central line-induced cardiac arrhythmia, and another received only 6 of 10 pl

155 iated with diseases including spherocytosis, cardiac arrhythmia, and bipolar disorder in humans, alth

156 to variation within known AF susceptibility, cardiac arrhythmia, and cardiomyopathy gene regions.

157 symptoms include seizures, lactic acidosis, cardiac arrhythmia, and death within days of birth.

158 ts included recurrent myocardial infarction, cardiac arrhythmia, and myocardial infarct size assessed

159 ons contribute to diseases such as epilepsy, cardiac arrhythmia, and neuromuscular symptoms collectiv

160 amidal symptoms, falls, cognitive worsening, cardiac arrhythmia, and pneumonia.

161 evere gastrointestinal toxicities, diabetes, cardiac arrhythmias, and death.

162 bnormalities of TLS can cause renal failure, cardiac arrhythmias, and death.

163 l cellular and tissue events associated with cardiac arrhythmias, and the molecular genetics of monog

164 Exome data from 22 cardiac arrhythmia- and 41 cardiomyopathy-associated gen

165 PURPOSE OF REVIEW: Cardiac arrhythmias are a major source of morbidity and

166 Many cardiac arrhythmias are caused by slowed conduction of a

167 Cardiac arrhythmias are common in Fabry disease (FD) and

168 Seizure-related cardiac arrhythmias are frequently reported and have bee

169 ith cardiac arrhythmias, mechanisms by which cardiac arrhythmias are generated in such genetic mutati

170 It is well known that various cardiac arrhythmias are initiated by an ill-timed excita

171 Cardiac arrhythmias are one of the most frequent causes

172 t, including stem cell-based models of human cardiac arrhythmias, are being deployed to study how per

173 e data represent the novel identification of cardiac arrhythmia as an early and progressive feature o

174 ion study identified atrial fibrillation and cardiac arrhythmias as the most common associated diagno

175 sentation, clinical course, and treatment of cardiac arrhythmias as well as the current understanding

176 ttack, peripheral arterial complication, and cardiac arrhythmia), as well.

177 , and CKM; contractile fiber gene ACTA1; and cardiac arrhythmia associated ion channel coding genes A

178 contributing to the increased risk of fatal cardiac arrhythmias associated with diabetic cardiac aut

179 otential (AP) repolarization and can trigger cardiac arrhythmias associated with long QT syndrome.

180 Furthermore, V4880A, a cardiac arrhythmia-associated mutation, markedly enhance

181 actions of drugs used for pain, epilepsy and cardiac arrhythmia at the atomic level.

182 (HIFU) has been introduced for treatment of cardiac arrhythmias because it offers the ability to cre

183 luoroquinolones have been suspected to cause cardiac arrhythmia but data are lacking, particularly fo

184 uld, in principle, be used not only to treat cardiac arrhythmias but also to repair other organs.

185 ts the concept that autoantibodies may cause cardiac arrhythmias but substantial experimental investi

186 Atrial fibrillation (AF) is the most common cardiac arrhythmia, but little is known about the molecu

187 Atrial fibrillation (AF) is the most common cardiac arrhythmia, but our knowledge of the arrhythmoge

188 requency ablation is routinely used to treat cardiac arrhythmias, but gaps remain in ablation lesion

189 uction are responsible for numerous forms of cardiac arrhythmias, but relatively little is known abou

190 mutation of one of these is associated with cardiac arrhythmia (C981F), induces a significant enhanc

191 t, homeostasis and pathologic states such as cardiac arrhythmias, cancer and trauma.

192 exomes to identify participants at risk for cardiac arrhythmias, cardiomyopathies, or sudden death.

193 Many patients with cardiac arrhythmias caused by mutations in SCN5A also ha

194 ecular basis of the neurologic disorders and cardiac arrhythmias caused by NaV channel mutations.

195 d on seizure-related respiratory depression, cardiac arrhythmia, cerebral depression, and autonomic d

196 ase, coronary artery disease, heart failure, cardiac arrhythmia, cerebrovascular disease, congenital

197 Predictors of CVA events were cardiac arrhythmia, Charlson comorbidity scores, history

198 nce/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive

199 cardial infarction, cerebrovascular disease, cardiac arrhythmias, dementia, and depression.

200 erous diseases including neuronal disorders, cardiac arrhythmia, diabetes, and asthma.

201 utations in common genes responsible for the cardiac arrhythmia disease, long QT syndrome (LQTS).

202 Long-QT syndrome (LQTS), a cardiac arrhythmia disorder with variable phenotype, oft

203 oratories experienced in genetic testing for cardiac arrhythmia disorders, there was low concordance

204 afterdepolarizations (EADs) are triggers of cardiac arrhythmia driven by L-type Ca(2+) current (ICaL

205 There were no increases in any cardiac arrhythmia during or after exposure to dilute di

206 We investigated the incidence of cardiac arrhythmias during and after controlled exposure

207 As a cellular precursor of lethal cardiac arrhythmias, early afterdepolarizations (EADs) d

208 mutations is an established cause of lethal cardiac arrhythmia, epilepsy, or painful syndromes.

209 the large majority of subjects experiencing cardiac arrhythmias from macrolides have coexisting risk

210 ad candidate pathogenic variants in dominant cardiac arrhythmia genes.

211 rmed among 25 AF patients in a comprehensive cardiac arrhythmia genetic panel.

212 ive, empirical technologies for treatment of cardiac arrhythmias has exceeded the pace at which detai

213 rt failure and channelopathies that underlie cardiac arrhythmias, have been elucidated.

214 Adverse events, including cardiac arrhythmia, heart, liver or renal dysfunction, o

215 0- and 90-day all-cause mortality and 90-day cardiac arrhythmias, heart failure, myocardial infarctio

216 tentials; these depolarized potentials cause cardiac arrhythmia; however, the underlying mechanism is

217 We examined relationships between cardiac arrhythmias, HRV, and exposures to airborne part

218 ified seven distinct patterns of (post)ictal cardiac arrhythmias: ictal asystole (103 cases), postict

219 al fibrillation is the most common sustained cardiac arrhythmia in adults.

220 They predispose young individuals to cardiac arrhythmia in the absence of structural abnormal

221 se of the cardiac action potential and cause cardiac arrhythmias in a variety of clinical settings.

222 er submersion can induce a high incidence of cardiac arrhythmias in healthy volunteers.

223 r the observed genetic link between Cav1 and cardiac arrhythmias in humans and suggest that targeted

224 ing the molecular and cellular mechanisms of cardiac arrhythmias in humans, and provides a robust ass

225 Atropine treatment reduced cardiac arrhythmias in mutant mice, implicating overacti

226 he findings offer a cellular basis for early cardiac arrhythmias in patients with arrhythmogenic card

227 beta-blockers prevent cardiac arrhythmias in patients with chronic heart failu

228 uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure.

229 tochasticity is likely to reduce the risk of cardiac arrhythmias in patients.

230 ance and markedly increases the incidence of cardiac arrhythmias in rats with HFpEF.

231 regulation of the CSPG4 locus led to lethal cardiac arrhythmias in the absence of cardiac dysfunctio

232 t may primarily contribute to the genesis of cardiac arrhythmias in Timothy Syndrome.

233 Ethnic differences in cardiac arrhythmia incidence have been reported, with a

234 recently found in a patient associated with cardiac arrhythmias including long QT.

235 Severe hypoglycemia caused numerous cardiac arrhythmias including premature ventricular cont

236 Alternans is a risk factor for cardiac arrhythmia, including atrial fibrillation.

237 tudies are often used to study mechanisms of cardiac arrhythmias, including atrial fibrillation (AF).

238 el beta2-subunits, are associated with human cardiac arrhythmias, including atrial fibrillation and B

239 annel Na(V)1.5, are associated with multiple cardiac arrhythmias, including Brugada syndrome.

240 (2+) signaling is implicated in a variety of cardiac arrhythmias, including catecholaminergic polymor

241 Most genes underlying inherited cardiac arrhythmias, including KCNE3, are not exclusivel

242 Cardiac arrhythmia is a leading cause of death, often re

243 ial fibrillation (AF), the most common human cardiac arrhythmia, is associated with abnormal intracel

244 roteins, including the cardiac-expressed and cardiac arrhythmia-linked transmembrane KCNE subunits.

245 ations were well identified in patients with cardiac arrhythmias, mechanisms by which cardiac arrhyth

246 ic receptor (beta-AR) activation can provoke cardiac arrhythmias mediated by cAMP-dependent alteratio

247 n chronic episodic disorders such as asthma, cardiac arrhythmias, migraine, epilepsy, and depression.

248 Associations of cardiac arrhythmia, myocardial ischemia, myocardial infa

249 el pathway that underlies the development of cardiac arrhythmia, namely NOX4 activation, subsequent N

250 Most cardiac arrhythmias occur intermittently.

251 Cardiac arrhythmias occurred early and in the absence of

252 Unexpectedly, cardiac arrhythmias occurred in >73% of deep, aerobic di

253 rillation (AF), the most prevalent sustained cardiac arrhythmia, often coexists with the related arrh

254 Atrial fibrillation, a common cardiac arrhythmia, often progresses unfavourably: in pa

255 grade 4 thrombocytopenia (one), and grade 3 cardiac arrhythmia (one).

256 rt failure (OR, 4.3; 95% CI, 3.0-6.3), prior cardiac arrhythmias (OR, 1.8; 95% CI, 1.2-2.7), previous

257 rates at the tissue scale to generate lethal cardiac arrhythmias over a wide range of heart rates.

258 ses a significant (4- to 5-fold) increase in cardiac arrhythmias (P<0.001) that worsened with age and

259 Phase analysis of cardiac arrhythmias, particularly atrial fibrillation, h

260 te variability, and may increase the risk of cardiac arrhythmias, particularly in susceptible patient

261 mmittee paused the trial to evaluate safety (cardiac arrhythmia, persistent acidosis, major vessel th

262 rial fibrillation, the most common sustained cardiac arrhythmia, remain poorly understood.

263 s in the connexin gene and the occurrence of cardiac arrhythmias remains largely unexplored.

264 ucidating the underlying mechanisms of fatal cardiac arrhythmias requires a tight integration of elec

265 Additionally, cardiac arrhythmia, respiratory control, and epilepsy ge

266 iac-Sirt1-deficient mice recapitulated human cardiac arrhythmias resulting from loss of function of N

267 ication, resulting in tachycardia, vomiting, cardiac arrhythmias, seizures, and death.

268 opean Heart Rhythm Association, and European Cardiac Arrhythmia Society consensus statement for the c

269 pean Society of Cardiology, and the European Cardiac Arrhythmia Society.

270 Genetic predisposition to life-threatening cardiac arrhythmias such as congenital long-QT syndrome

271 rdiac rhythms, which have been implicated in cardiac arrhythmias such as T-wave alternans and various

272 e regional ischemia in the heart can lead to cardiac arrhythmias such as ventricular fibrillation (VF

273 ding the anatomical substrate for re-entrant cardiac arrhythmias such as Wolff-Parkinson-White syndro

274 in human Kv7.1 and KCNE1 genes, which cause cardiac arrhythmias, such as the long-QT syndrome (LQT)

275 lators in cardiovascular disorders including cardiac arrhythmia susceptibility, cardiac conduction ph

276 exertional angina, acute coronary syndromes, cardiac arrhythmias, syncope, or even sudden cardiac dea

277 ically available genetic tests for heritable cardiac arrhythmia syndromes allow the identification of

278 val fibromatosis is an allelic disorder with cardiac arrhythmia syndromes caused by KCNQ1 mutations.

279 the genetic substrates underlying heritable cardiac arrhythmia syndromes has unearthed new arrhythmo

280 rare variant interpretation in the heritable cardiac arrhythmia syndromes, focusing on recent advance

281 ed gene defects can cause potentially lethal cardiac arrhythmia syndromes, including catecholaminergi

282 e been associated with a number of inherited cardiac arrhythmia syndromes, including Timothy, Brugada

283 Atrial fibrillation (AF) is a cardiac arrhythmia that arises from electrical and contr

284 Intriguingly, NOX4 embryos developed cardiac arrhythmia that is characterized by irregular he

285 lation (AF) is the most commonly encountered cardiac arrhythmia, the basic mechanisms underlying this

286 ion produces Long QT syndrome and the lethal cardiac arrhythmia torsade de pointes.

287 severe hypoglycemia were mediated by lethal cardiac arrhythmias triggered by brain neuroglycopenia a

288 The incidence of cardiac arrhythmias was recorded for each exposure and s

289 A similar noninvasive treatment modality for cardiac arrhythmias was tested here.

290 minant myoclonus-dystonia-like syndrome with cardiac arrhythmias, we identified a mutation in the CAC

291 e annulus fibrosis and the etiology of these cardiac arrhythmias, we used Cre-LoxP technology to asse

292 In summary, severe hypoglycemia-induced cardiac arrhythmias were increased by insulin deficiency

293 ion of left ventricle ejection fraction, and cardiac arrhythmias were reduced.

294 al fibrillation is the most common sustained cardiac arrhythmia, which is associated with a high risk

295 thm of a human heart may result in different cardiac arrhythmias, which may be immediately fatal or c

296 advances have enabled noninvasive mapping of cardiac arrhythmias with electrocardiographic imaging an

297 bles comprehensive noninvasive assessment of cardiac arrhythmias, with potential applications for dia

298 ventricular tachycardia that feature lethal cardiac arrhythmias without structural abnormality.

299 of hERG channels is critical for preventing cardiac arrhythmia yet the mechanistic basis for the slo

300 brillation (AF) is the most common sustained cardiac arrhythmia, yet current pharmacological treatmen